Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory/relapsed acute myeloid leukemia.
Ni Lu, Li Liu, Yigeng Cao...
https://pubmed.ncbi.nlm.nih.gov/40353947Actively Recruiting
All Genders
ID04645199
National Longitudinal Cohort of Hematological Diseases (NICHE)
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-02-12
2300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a large-scale, long-term observational study to better understand major blood diseases in China. This study aims to analyze the incidence, risk factors, treatments, prognosis, and medical costs related to various hematological conditions such as acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders, autoimmune hemolytic anemia, and others. The study includes patients who have received bone marrow transplantation and fills a gap due to limited prior cohort data in China. The study collects information from patients diagnosed with these blood diseases in participating hospitals starting from January 1, 2020. It gathers data prospectively and retrospectively from medical records, including basic patient information, diagnosis, treatment details, prognosis, and medical expenses. The NICHE registry includes historical data from 2000 and continues to collect prospective follow-up data in phases, broadening its reach. Participants' data will be monitored over at least five years to assess the incidence and distribution of blood diseases, evaluate treatments, and analyze healthcare costs. The study does not involve experimental treatments but focuses on collecting and analyzing real-world clinical information. Researchers will use this data to better understand disease patterns and outcomes, with follow-ups planned to gather ongoing prognosis details and economic evaluations.
CONDITIONS
Brief Title
National Longitudinal Cohort of Hematological Diseases
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders, or who received bone marrow transplantation in the investigating hospitals from January 1, 2020
You will not qualify if you...
- Patients without long-term follow-up information available for any reason, including serious concomitant disease
- Patients with alcohol or drug addictions affecting their ability to comply with study requirements
- Patients with conditions that may endanger safety or affect compliance as determined by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 5 years
Participants are observed over time to collect long-term data on their hematological diseases.
Periodic visits depending on clinical follow-up
Trial Site Locations
Total: 1 location
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 300000
Actively Recruiting
Loading map...
Research Team
Z
Zhen Song, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma.
Wenqiang Yan, Lihui Shi, Jingyu Xu...
https://pubmed.ncbi.nlm.nih.gov/39095502Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort.
Hongye Gao, Jiali Wang, Xinhui Zheng...
https://pubmed.ncbi.nlm.nih.gov/38505288Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma.
Jian Cui, Tengteng Yu, Rui Lv...
https://pubmed.ncbi.nlm.nih.gov/38249329Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
Huishou Fan, Bing Wang, Lihui Shi...
https://pubmed.ncbi.nlm.nih.gov/38170583Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.
Wenqiang Yan, Jingyu Xu, Huishou Fan...
https://pubmed.ncbi.nlm.nih.gov/37846845Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
Jiahui Liu, Wenqiang Yan, Huishou Fan...
https://pubmed.ncbi.nlm.nih.gov/37680953Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.
Jian Cui, Rui Lv, Tengteng Yu...
https://pubmed.ncbi.nlm.nih.gov/37534514Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.
Huishou Fan, Weida Wang, Ya Zhang...
https://pubmed.ncbi.nlm.nih.gov/36647781